Impact of public health strategies on the birth prevalence of cystic fibrosis in Brittany, France

被引:22
作者
Scotet, V
Audrézet, MP
Roussey, M
Rault, G
Blayau, M
De Braekeleer, M
Férec, C
机构
[1] Hosp Univ, EFS Bretagne, Lab Genet Mol & Histocompatibil, INSERM EMI 01 15, F-29275 Brest, France
[2] CHRU, Hop Sud, Rennes, France
[3] Ctr Perharidy, Roscoff, France
[4] Mol Genet Lab, Rennes, France
[5] Lab Cytogenet, Brest, France
[6] Inst Natl Etud Demog, Paris, France
关键词
D O I
10.1007/s00439-003-0962-0
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Taking into account the situation of Brittany, a region of western France where cystic fibrosis (CF) is common and where a neonatal screening program was set up 14 years ago, the aim of this study was to determine the way in which the birth prevalence of CF has been influenced by the various public health strategies implemented in the region (neonatal screening, prenatal diagnosis, ultrasound examination and family testing). This study used the results of the neonatal screening program, which enabled a precise measure of the prevalence of CF at birth to be obtained. Over the same period, we collected data from prenatal diagnoses carried out in the region, first in families related to a CF child and also those made following the detection of an echogenic bowel upon routine ultrasound examination performed during pregnancy. The prevalence of CF at birth was estimated to be 1/2838 in the region over a 10-year period (1992-2001). By including the 54 CF-affected pregnancies that were terminated during these 10 years, the corrected birth prevalence of CF was 1/1972. Prenatal diagnosis was therefore responsible for a global decrease in CF prevalence at birth of 30.5%. This work constitutes the first study able to provide a precise measure of CF birth prevalence and of its evolution through the combined effects of neonatal screening, prenatal diagnosis, ultrasound examination and family testing.
引用
收藏
页码:280 / 285
页数:6
相关论文
共 31 条
[1]   Cystic fibrosis and chromosome abnormalities associated with echogenic fetal bowel [J].
Berlin, BM ;
Norton, ME ;
Sugarman, EA ;
Tsipis, JE ;
Allitto, BA .
OBSTETRICS AND GYNECOLOGY, 1999, 94 (01) :135-138
[2]   Cystic fibrosis: A worldwide analysis of CFTR mutations - Correlation with incidence data and application to screening [J].
Bobadilla, JL ;
Macek, M ;
Fine, JP ;
Farrell, PM .
HUMAN MUTATION, 2002, 19 (06) :575-606
[3]  
BOUE A, 1986, HUM GENET, V74, P288
[4]   Genetic counseling and neonatal screening for cystic fibrosis: An assessment of the communication process [J].
Ciske, DJ ;
Haavisto, A ;
Laxova, A ;
Rock, LZM ;
Farrell, PM .
PEDIATRICS, 2001, 107 (04) :699-705
[5]  
Cornel M C, 1999, Community Genet, V2, P162, DOI 10.1159/000016206
[6]   Nutritional benefits of neonatal screening for cystic fibrosis [J].
Farrell, PM ;
Kosorok, MR ;
Laxova, A ;
Shen, GH ;
Koscik, RE ;
Bruns, WT ;
Splaingard, M ;
Mischler, EH .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (14) :963-969
[7]   Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth [J].
Farrell, PM ;
Kosorok, MR ;
Rock, MJ ;
Laxova, A ;
Zeng, L ;
Lai, HC ;
Hoffman, G ;
Laessig, RH ;
Splaingard, ML .
PEDIATRICS, 2001, 107 (01) :1-13
[8]  
FEINGOLD J, 1974, ANN GENET-PARIS, V17, P257
[9]   NEONATAL SCREENING FOR CYSTIC-FIBROSIS - RESULT OF A PILOT-STUDY USING BOTH IMMUNOREACTIVE TRYPSINOGEN AND CYSTIC-FIBROSIS GENE MUTATION ANALYSES [J].
FEREC, C ;
VERLINGUE, C ;
PARENT, P ;
MORIN, JF ;
CODET, JP ;
RAULT, G ;
DAGORNE, M ;
LEMOIGNE, A ;
JOURNEL, H ;
ROUSSEY, M ;
LEMAREC, B ;
CATHELINE, M ;
AUDREZET, MP ;
MERCIER, B .
HUMAN GENETICS, 1995, 96 (05) :542-548
[10]   DETECTION OF OVER 98-PERCENT CYSTIC-FIBROSIS MUTATIONS IN A CELTIC POPULATION [J].
FEREC, C ;
AUDREZET, MP ;
MERCIER, B ;
GUILLERMIT, H ;
MOULLIER, P ;
QUERE, I ;
VERLINGUE, C .
NATURE GENETICS, 1992, 1 (03) :188-191